Molecure SA MOC
GPW · Poland · Health Technology
PLN 7.14+0.24 (+3.48%)
Market closed· · PLN · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · PLN · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Recently published Sarcoidosis Market Insights report includes a comprehensive understanding of current treatment practices, sarcoidosis emerging drugs, market share of individual therapies, and current and forecasted market size from 2022 to 2036, segmented into leading markets [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].
The Independent Data Monitoring Committee (IDMC) recommended continuation of the global Phase II PoC study in patients with active pulmonary sarcoidosis without changes to the current protocol.The recommendation followed the IDMC’s review of the complete safety and efficacy dataset for an interim analysis in 30 patients.Based on unblinded data, a futility analysis indicated sufficient probability of achieving the primary endpoint—based on differences in PET/CT imaging—and selected secondary endp
DelveInsight's DUB Inhibitors Market Size, Target Population, Competitive Landscape & Market Forecast report includes a comprehensive understanding of current treatment practices, addressable patient population, which includes top indications such as Heart Failure, Parkinson's Disease, Alzheimer's Disease, Lymphoma, Breast Cancer, and others. The selected indications are based on approved therapies and ongoing pipeline activity. The report also provides insights into the emerging DUB inhibitors,
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.